Development of Magnetic Based Nano Carrier Formulation of Few Drugs and their Evaluation for Targeted Drug Delivery in Breast Cancer

dc.contributor.guideSingh, Namrata
dc.coverage.spatial
dc.creator.researcherWagh, Kalpeshkumar Shamkant
dc.date.accessioned2025-09-01T09:04:46Z
dc.date.available2025-09-01T09:04:46Z
dc.date.awarded2025
dc.date.completed2025
dc.date.registered2019
dc.description.abstractCancer, characterized by the uncontrolled proliferation of abnormal cells, presents significant challenges in treatment. This study explores the formulation, characterization, and biocompatibility of magnetic nanoparticles (MNPs) conjugated with Docetaxel (DCX) and Tamoxifen Citrate (TMX) for targeted cancer therapy. The MNPs were synthesized using a co-precipitation method, functionalized with arginine, and conjugated with DCX and TMX through covalent bonds. Various analytical techniques, including FTIR, XRD, TEM, VSM, and DLS, were employed to characterize the physicochemical properties of the nanoparticles. The FTIR spectra confirmed the successful functionalization and conjugation processes. XRD patterns and TEM images demonstrated the crystalline structure and uniform size distribution of the nanoparticles, with mean diameters of 26.99 nm for Fe-Arg-DCX and 32.15 nm for Fe-Arg-TMX. VSM analysis revealed a reduction in magnetization values post- functionalization, indicating successful surface modification. Thermal analysis through TGA and DSC showed the stability of the conjugated nanoparticles. Biocompatibility was assessed via hemolysis and cell viability assays. The hemolysis assay indicated minimal hemolytic activity, confirming excellent blood compatibility. In vitro cytotoxicity studies using HFF-2, MCF-7, and 4T1 cell lines demonstrated that Fe-Arg-DCX and Fe-Arg-TMX nanoparticles exhibited superior inhibitory effects on cancer cells compared to free drugs. The IC50 values of the conjugated nanoparticles were significantly lower, highlighting their enhanced efficacy. Drug release studies under lysosomal conditions revealed a sustained release profile, with the presence of proteinase K enzyme accelerating the release of DCX and TMX. newline
dc.description.note
dc.format.accompanyingmaterialDVD
dc.format.dimensions
dc.format.extent
dc.identifier.researcherid0009-0008-6825-5882
dc.identifier.urihttp://hdl.handle.net/10603/660621
dc.languageEnglish
dc.publisher.institutionPharmacy
dc.publisher.placeIndore
dc.publisher.universityOriental University
dc.relation
dc.rightsuniversity
dc.source.universityUniversity
dc.subject.keywordCancer
dc.subject.keywordClinical Pre Clinical and Health
dc.subject.keywordmagnetic nanoparticles
dc.subject.keywordPharmacology and Pharmacy
dc.subject.keywordPharmacology and Toxicology
dc.titleDevelopment of Magnetic Based Nano Carrier Formulation of Few Drugs and their Evaluation for Targeted Drug Delivery in Breast Cancer
dc.title.alternative
dc.type.degreePh.D.

Files

Original bundle

Now showing 1 - 5 of 14
Loading...
Thumbnail Image
Name:
01_title page.pdf
Size:
130.14 KB
Format:
Adobe Portable Document Format
Description:
Attached File
Loading...
Thumbnail Image
Name:
02_preliminary pages.pdf
Size:
396.18 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
03_content.pdf
Size:
195.73 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
04_abstract.pdf
Size:
90.11 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
05_chapter�1.pdf
Size:
1.07 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:

Collections